Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-OIV H1N1 vaccine
- Development stage
- Unknown
- Lead developer
- The University of Hong Kong
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
The S-OIV H1N1 vaccine refers to a monovalent influenza vaccine targeting the 2009 pandemic swine-origin influenza A (H1N1) virus. In studies conducted by The University of Hong Kong, this vaccine was evaluated for dose-sparing efficacy using intradermal delivery via the MicronJet600 microneedle device. The research aimed to demonstrate that a reduced dose (20% of standard) delivered intradermally could elicit an immune response non-inferior to the standard intramuscular dose, thereby potentially increasing vaccine availability during pandemic shortages.
- Other names
- Swine-origin influenza virus H1N1 vaccinePandemic H1N1 2009 vaccineH1N1 influenza vaccineH-1N1 influenza vaccineH 1N1 influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on S-OIV H1N1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-OIV H1N1 vaccine.